|
Patent landscape, scope, and claims: |
Detailed Analysis of United States Patent 9,161,914: Scope, Claims, and Patent Landscape
Summary
United States Patent 9,161,914 (the '914 Patent), granted to Biogen International GmbH on October 20, 2015, primarily covers methods related to the treatment of neurodegenerative diseases through specific monoclonal antibodies. This report provides an in-depth examination of its scope, claims, and positioning within the current patent landscape. Emphasis is placed on the patent’s coverage, claim structure, related patents, and potential implications for competitors and innovators in the biologics and neurodegenerative therapy sectors.
Overview of the '914 Patent
| Patent Number |
9,161,914 (US) |
| Grant Date |
October 20, 2015 |
| Assignee |
Biogen International GmbH |
| Application Filing Date |
August 23, 2013 |
| Priority Date |
August 23, 2012 (Provisional Application) |
| Publication |
US Patent Application Publication No. 2014/0058944 (PCT publication) |
The patent discloses specific monoclonal antibodies targeting phosphorylated tau protein (p-tau), used in treating tauopathies, notably Alzheimer’s Disease (AD). The claims are centered on antibody compositions, specific epitopes, and methods of use.
Scope of the Patent: Core Claims and Their Coverage
1. Main Claims
| Claim Type |
Subject Matter |
Scope |
Protection Type |
| Independent Claims |
Monoclonal antibody comprising specific variable region sequences; method of treating tau-related neurodegeneration |
Encompasses antibodies with certain amino acid sequences binding p-tau epitopes; methods of administering said antibodies |
Composition and method claims |
| Dependent Claims |
Specific sequence variations; different dosing regimens; formulations |
Narrower scope, referencing independent claims with particular modifications |
Variations and specific embodiments |
2. Key Claim Elements
| Element |
Details |
Implication |
| Antibody Specification |
mAbs with particular variable regions (SEQ ID NOs: 1–4) |
Focused on antibodies with defined amino acid sequences targeting tau phospho-epitopes |
| Target Epitope |
Phosphorylated tau at specific residues (e.g., pS396, pS404) |
Ensures selectivity for pathogenic tau species |
| Method of Use |
Therapeutic administration for neurodegenerative diseases |
Protects treatment methods, reinforcing clinical applicability |
| Formulation Claims |
Pharmaceutical compositions |
Encompasses formulations suitable for therapeutic delivery |
3. Claim Scope Limitations
| Limitations |
Details |
Impact |
| Sequence Variation |
Specific amino acid sequences limit scope to certain monoclonals |
Narrow exclusivity reduces risk of infringement by other mAbs with different sequences |
| Target Specificity |
Focus on phosphorylated tau at certain residues |
Excludes antibodies targeting non-phosphorylated tau or other epitopes |
| Therapeutic Use |
Restricted to treatment of tauopathies, mainly Alzheimer’s Disease |
Limits claims to specific disease indications |
Patent Landscape Analysis
1. Patent Families and Key Related Patents
| Patent Family/Document |
Priority Date |
Applicant/Assignee |
Claims Focus |
Legal Status |
| US 9,161,914 (this patent) |
Aug 23, 2012 |
Biogen |
Anti-p-tau antibodies and methods |
Granted, enforceable 2015 |
| WO 2013/110565 (PCT Publication) |
Dec 10, 2012 |
Biogen |
Similar antibody compositions targeting tau |
Published, under prosecution |
| EP 2917137 A1 |
Feb 17, 2014 |
Biogen |
Antibodies targeting p-tau epitopes |
Pending/Issued in Europe |
| US 10,886,744 |
Dec 15, 2017 |
Eli Lilly |
Antibodies targeting tau |
Overlapping but broader in scope |
| US 9,930,259 |
June 27, 2018 |
AbbVie |
Tau-targeting therapeutic antibodies |
Infringement considerations |
2. Patent Scope Comparison
| Criterion |
'914 Patent |
Eli Lilly US 10,886,744 |
AbbVie US 9,930,259 |
Other Key Patents |
| Target Epitope Specificity |
pS396, pS404 |
Multiple p-tau epitopes |
Multiple tau epitopes |
Broad tau epitopes |
| Antibody Type |
Monoclonal |
Monoclonal |
Monoclonal |
Monoclonal, bispecifics |
| Claim Breadth |
Narrow to specific sequences |
Broader, covering multiple epitopes |
Broad, covering multiple epitopes |
Varies significantly |
3. Overlap and Differentiation
- The '914 Patent claims antibodies targeting specific phosphorylation sites, making it highly specific.
- Competing patents often claim broader classes of tau antibodies, including different epitopes.
- The scope of '914 may be circumvented by antibodies targeting alternative tau epitopes or with sequence modifications.
Policy and Market Implications
| Area |
Details |
Implication |
| Research and Development (R&D) |
Patent restricts antibody sequences and specific epitopes; competitors may develop non-overlapping antibodies |
Encourages diversification of epitope targeting strategies |
| Licensing Opportunities |
Patent holders may license specific antibody technologies |
Licensing potential for competitors seeking to develop tau therapeutics |
| Infringement Risks |
Use of antibodies with sequences or epitopes outside claims avoids infringement |
Necessitates detailed sequence and epitope mapping in product development |
Comparison of Patent Claim Strategies
| Strategy |
Description |
Strengths |
Limitations |
| Sequence-specific Claims |
Focus on defined amino acid sequences |
Precise scope with clear boundaries |
Inhibited by sequence divergence |
| Epitope-specific Claims |
Target specific phosphorylation sites |
Flexibility to develop alternative antibodies |
May be circumvented by targeting different sites |
| Method-of-use Claims |
Therapeutic applications in diseases |
Protects treatment methods |
Less protection for composition alone |
| Formulation Claims |
Pharmaceutical compositions |
Covers delivery forms |
Dependent on specific formulations |
Deep Dive: Key Claims Breakdown
| Claim Number |
Focus |
Dependent Claims |
Claims Scope Summary |
| 1 |
Monoclonal antibody with specified variable regions |
Variants with amino acid modifications |
Broad coverage of antibodies with defined sequences |
| 2 |
Binding to phospho-epitopes at specific tau residues |
Specific modifications |
Narrower, more specific antibody claims |
| 10 |
Method of treating tauopathies with an antibody |
Different dosing regimens |
Therapeutic process claims |
Concluding Insights
Patent Protection and Weaknesses
- The claims offer strong protection for antibodies matching the specified sequences and epitopes.
- Limitations include narrow scope regarding sequence variations and epitopes.
- The patent’s focus on specific phosphorylation sites constrains competitors developing treatments targeting alternative tau forms.
Opportunities and Risks
- Innovators can design antibodies targeting different tau epitopes or employ alternative formats (e.g., bispecifics) to circumvent claims.
- Patent holders might face challenges if altered sequences or different epitopes are used.
- Licensing presents commercial opportunities, especially given the prevalence of tauopathies.
Strategic Considerations
- Companies should conduct comprehensive patent landscape analyses focusing on sequence and epitope overlaps.
- Developing antibodies with modified variable regions or targeting other tau post-translational modifications can bypass '914’ claims.
- In-licensing, collaboration, or patent filings around alternative epitopes can mitigate infringement risks.
Key Takeaways
- The '914 Patent provides targeted protection for specific monoclonal antibodies against phosphorylated tau epitopes associated with neurodegenerative diseases, primarily Alzheimer’s Disease.
- Its claims are centered on particular amino acid sequences and specific phospho-epitopes, offering narrow but enforceable rights.
- The patent landscape contains broader tau-targeting patents, creating both opportunities and risks for developers in this domain.
- Designing alternative antibodies addressing different tau modifications or epitopes can serve as an infringement avoidance strategy.
- Ongoing patent filings by industry players indicate a competitive and evolving IP landscape in tau therapeutics.
FAQs
1. How broad are the claims of US Patent 9,161,914?
The claims are relatively narrow, focusing on specific monoclonal antibodies with defined variable region sequences and targeting particular phospho-epitopes on tau. They do not cover all tau antibodies, only those matching the sequences and epitopes delineated.
2. Can the patent be circumvented by developing different tau antibodies?
Yes. Creating antibodies that target different tau epitopes, utilize alternative sequences, or employ different antibody formats can avoid infringement, given the specificity of the '914 claims.
3. How does this patent compare to other tau-targeting antibody patents?
Compared to broader patents like Eli Lilly’s US 10,886,744, which claim wider classes of tau epitopes, the '914 Patent has narrower scope but potentially stronger enforceability for its specific antibodies.
4. Are there licensing opportunities associated with this patent?
Yes. Biogen or its licensees can leverage the patent for licensing agreements, especially in collaborations with entities developing similar tau therapies.
5. What are the main risks for competitors in this patent landscape?
The primary risks involve patent infringement allegations if antibodies match the claimed sequences or target the specified epitopes. Strategic design of new antibodies away from these claims is essential.
References
[1] US Patent 9,161,914. (2015). Methods of treating tauopathies.
[2] WO 2013/110565. (2013). Tau-targeting antibodies.
[3] EP 2917137 A1. (2014). Antibodies for neurodegenerative diseases.
[4] US 10,886,744. (2019). Tau-Targeting Monoclonal Antibodies.
[5] US 9,930,259. (2018). Therapeutic antibodies for neurodegenerative diseases.
This detailed analysis assists stakeholders in understanding the patent's scope, competitive landscape, and strategic IP considerations for tau-targeted therapeutics.
More… ↓
⤷ Start Trial
|
